Emergent Biosolutions, Inc. (NYSE:EBS) Chairman Fuad El-Hibri sold 25,000 shares of the company’s stock in a transaction that occurred on Thursday, July 20th. The shares were sold at an average price of $35.50, for a total value of $887,500.00. Following the sale, the chairman now owns 1,655,216 shares in the company, valued at approximately $58,760,168. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of Emergent Biosolutions, Inc. (NYSE:EBS) traded down 0.36% during mid-day trading on Friday, hitting $35.91. The stock had a trading volume of 271,376 shares. The stock has a market cap of $1.47 billion, a price-to-earnings ratio of 28.55 and a beta of 1.21. The firm has a 50 day moving average of $33.28 and a 200 day moving average of $31.00. Emergent Biosolutions, Inc. has a one year low of $24.47 and a one year high of $36.64.

Emergent Biosolutions (NYSE:EBS) last announced its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported $0.23 EPS for the quarter, missing analysts’ consensus estimates of $0.31 by $0.08. The business had revenue of $116.90 million for the quarter, compared to the consensus estimate of $121.30 million. Emergent Biosolutions had a return on equity of 11.92% and a net margin of 10.36%. The firm’s revenue for the quarter was up 13.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.16 EPS. On average, analysts forecast that Emergent Biosolutions, Inc. will post $1.58 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Emergent Biosolutions, Inc. (NYSE:EBS) Chairman Fuad El-Hibri Sells 25,000 Shares” was reported by American Banking News and is the property of of American Banking News. If you are reading this news story on another domain, it was illegally copied and republished in violation of United States and international trademark & copyright law. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/07/21/emergent-biosolutions-inc-nyseebs-chairman-fuad-el-hibri-sells-25000-shares.html.

Several analysts have issued reports on the company. Zacks Investment Research cut Emergent Biosolutions from a “hold” rating to a “sell” rating in a research note on Monday. BidaskClub upgraded Emergent Biosolutions from a “hold” rating to a “buy” rating in a research note on Saturday, June 24th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company’s stock. Emergent Biosolutions has a consensus rating of “Buy” and a consensus price target of $39.25.

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Aperio Group LLC boosted its position in shares of Emergent Biosolutions by 5.3% in the second quarter. Aperio Group LLC now owns 11,644 shares of the biopharmaceutical company’s stock worth $395,000 after buying an additional 589 shares in the last quarter. Louisiana State Employees Retirement System boosted its position in shares of Emergent Biosolutions by 0.7% in the second quarter. Louisiana State Employees Retirement System now owns 14,200 shares of the biopharmaceutical company’s stock worth $482,000 after buying an additional 100 shares in the last quarter. Eqis Capital Management Inc. boosted its position in shares of Emergent Biosolutions by 0.7% in the second quarter. Eqis Capital Management Inc. now owns 38,382 shares of the biopharmaceutical company’s stock worth $1,302,000 after buying an additional 271 shares in the last quarter. State of Alaska Department of Revenue boosted its position in shares of Emergent Biosolutions by 79.9% in the second quarter. State of Alaska Department of Revenue now owns 6,871 shares of the biopharmaceutical company’s stock worth $232,000 after buying an additional 3,051 shares in the last quarter. Finally, Creative Planning boosted its position in shares of Emergent Biosolutions by 1.2% in the second quarter. Creative Planning now owns 4,555 shares of the biopharmaceutical company’s stock worth $154,000 after buying an additional 55 shares in the last quarter. Hedge funds and other institutional investors own 85.89% of the company’s stock.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).

Receive News & Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.